Impact of Sjögren’s disease and its immunological characteristics on reaching remission or low disease activity state in systemic lupus erythematosus patients: a propensity score-matched longitudinal study
Haoze Zhang, Huijuan Zhang, Dai Gao, Lanlan Ji, Yanjie Hao, Zhuoli Zhang
TL;DR
This study finds that Sjögren’s disease affects how lupus patients reach remission or low disease activity, with some immune features helping or hindering progress.
Contribution
The study identifies specific Sjögren’s disease characteristics that influence lupus remission and low disease activity in a real-world cohort.
Findings
Overlapping Sjögren’s disease and anti-SSA/SSB positivity reduced remission on treatment in lupus patients.
Sjögren’s disease with baseline hypergammaglobulinemia increased likelihood of low disease activity.
Anti-SSA single positivity had no significant effect on remission achievement.
Abstract
Systemic lupus erythematosus (SLE) overlapping with Sjögren’s disease (SjD) or not may progress differently in the clinical course. We aimed to explore the impact of SjD on lupus low disease activity state (LLDAS) or remission achievement in a real-world cohort. The medical records of patients in the Peking University First Hospital SLE (PKUFHS) cohort from 2007 to 2019 were retrospectively reviewed. Demographics, SLE and SjD features, treatment, and whether in LLDAS/remission on treatment (RONT) or not at each visit were collected. According to overlapped SjD and its immunological features, all patients were categorized into the following subgroups: SjD with anti-SSA single positivity, SjD with anti-SSA/SSB double positivity, SjD with baseline hypergammaglobulinemia, and those without SjD. The Cox proportional hazards model in propensity score-matched cohorts was used to estimate the…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
| SLE without SjD (n = 549) | SLE with SjD features | ||||
|---|---|---|---|---|---|
| SjD (n = 77) | Anti-SSA single-positive SjD (n = 35) | Anti-SSA/B-double-positive SjD (n = 34) | SjD with HG (n = 51) | ||
| LLDAS at least once, n (%) | 355 (64.7) | 58 (75.3) | 27 (77.1) | 25 (73.5) | 41 (80.4)* |
| Time to first LLDAS, median (IQR) months | 20.0 (12.0, 33.0) | 19.5 (15.0, 30.0) | 20.0 (10.0, 34.0) | 18.0 (16.0, 31.0) | 18.0 (14.0, 26.0) |
| Time ratio on LLDAS during follow-up, median (IQR) % | 18.2 (0.0, 52.1) | 25.0 (0.0, 53.3) | 25.5 (0.0, 55.7) | 23.2 (0.0, 61.8) | 34.6 (12.5, 60.0)* |
| Clinical RONT at least once, n (%) | 218 (39.7) | 37 (48.1) | 19 (54.3) | 14 (41.2) | 29 (56.9)* |
| Time to first clinical RONT, median (IQR) months | 21.0 (14.0, 38.0) | 23.0 (16.0, 35.0) | 23.0 (14.0, 34.0) | 26.5 (16.0, 37.0) | 22.0 (15.0, 31.0) |
| Time ratio on clinical RONT during follow-up, median (IQR) % | 0.0 (0.0, 20.2) | 0.0 (0.0, 25.0) | 11.2 (0.0, 32.6) | 0.0 (0.0, 23.1) | 5.6 (0.0, 36.2)* |
| Complete RONT at least once, n (%) | 191 (34.8) | 35 (45.5) | 19 (54.3)* | 12 (35.3) | 27 (52.9)* |
| Time to first complete RONT, median (IQR) months | 22.0 (14.0, 38.0) | 24.0 (15.0, 37.0) | 23.0 (14.0, 35.0) | 30.0 (18.0, 38.0) | 23.0 (14.0, 35.0) |
| Time ratio on complete RONT during follow-up, median (IQR) % | 0.0 (0.0, 12.5) | 0.0 (0.0, 21.7) | 8.3 (0.0, 25.0)* | 0.0 (0.0, 18.2) | 0.0 (0.0, 32.6)* |
|
| Overlapping SjD | Anti-SSA single-positive SjD | Anti-SSA/SSB double-positive SjD | Overlapping SjD with baseline HG | ||||
|---|---|---|---|---|---|---|---|---|
| Unmatched | Matched | Unmatched | Matched | Unmatched | Matched | Unmatched | Matched | |
| LLDAS | 1.11 (0.98–1.24) | 1.24 (1.08–1.44)† | 1.12 (0.96–1.30) | 1.17 (0.94–1.44) | 0.99 (0.83–1.20) | 0.95 (0.78–1.16) | 1.34 (1.16–1.54)† | 1.31 (1.12–1.54)† |
| SLEDAI ≤ 4 | 1.11 (1.03–1.19)† | 1.15 (1.05–1.26)† | 1.02 (0.92–1.13) | 0.95 (0.83–1.08) | 1.11 (0.99–1.24) | 1.05 (0.93–1.19) | 1.22 (1.11–1.33)† | 1.12 (1.01–1.24)* |
| No new feature | 1.01 (0.93–1.08) | 1.03 (0.94–1.13) | 0.91 (0.82–1.01) | 0.95 (0.83–1.09) | 1.03 (0.92–1.15) | 0.96 (0.85–1.08) | 1.09 (1.00–1.20) | 1.07 (0.96–1.18) |
| No active organ involvement | 1.08 (1.00–1.17)* | 1.08 (0.98–1.18) | 1.03 (0.93–1.13) | 1.00 (0.88–1.14) | 1.05 (0.93–1.18) | 1.00 (0.88–1.13) | 1.17 (1.06–1.28)† | 1.05 (0.94–1.16) |
| Clinical RONT | 1.03 (0.86–1.23) | 0.71 (0.55–0.92)† | 1.29 (1.04–1.58)* | 0.75 (0.53–1.06) | 0.63 (0.45–0.88)† | 0.50 (0.35–0.73)† | 1.39 (1.14–1.71)† | 1.25 (0.98–1.59) |
| Complete RONT | 1.05 (0.87–1.27) | 0.62 (0.46–0.83)† | 1.34 (1.08–1.67)† | 0.84 (0.58–1.22) | 0.59 (0.41–0.85)† | 0.47 (0.31–0.70)† | 1.49 (1.21–1.84)† | 1.30 (1.01–1.68)* |
| cSLEDAI = 0 | 1.16 (1.07–1.26)† | 1.17 (1.06–1.30)† | 1.05 (0.94–1.17) | 0.98 (0.85–1.14) | 1.15 (1.02–1.30)* | 1.12 (0.98–1.28) | 1.26 (1.14–1.40)† | 1.16 (1.04–1.29)† |
| Normal serology | 1.12 (1.01–1.24)* | 0.85 (0.73–0.98)* | 1.30 (1.14–1.47)† | 0.99 (0.82–1.20) | 0.85 (0.71–1.01) | 0.64 (0.52–0.78)† | 1.27 (1.12–1.44)† | 1.24 (1.07–1.43)† |
| Negative anti-dsDNA | 1.07 (0.97–1.17) | 0.84 (0.74–0.96)† | 1.25 (1.11–1.40)† | 0.96 (0.82–1.13) | 0.82 (0.70–0.97)* | 0.65 (0.54–0.78)† | 1.21 (1.08–1.35)† | 1.15 (1.01–1.31)* |
| PGA ≤ 1 | 1.15 (1.07–1.24)† | 1.12 (1.01–1.24)* | 1.06 (0.95–1.17) | 1.02 (0.88–1.18) | 1.13 (1.01–1.27)* | 1.05 (0.92–1.20) | 1.27 (1.16–1.40)† | 1.23 (1.10–1.37)† |
| Pred ≤ 5 mg/d | 1.02 (0.95–1.10) | 1.06 (0.97–1.15) | 0.94 (0.86–1.04) | 0.96 (0.84–1.08) | 1.04 (0.93–1.15) | 0.98 (0.87–1.10) | 1.10 (1.01–1.20)* | 1.06 (0.96–1.17) |
| No immunosuppressant | 1.03 (0.92–1.16) | 1.19 (1.04–1.37)* | 1.10 (0.95–1.27) | 1.16 (0.94–1.43) | 0.88 (0.73–1.05) | 0.83 (0.68–1.01) | 1.24 (1.09–1.42)† | 1.17 (1.00–1.36)* |
| Gender | Age of onset | Duration | Low treatment | Low activity | Renal involvement | Hematological involvement | NP-SLE | |
|---|---|---|---|---|---|---|---|---|
| LLDAS | ||||||||
| Overlapping SjD | 1.25 (1.08–1.44)† | 1.10 (0.95–1.28) | 1.20 (1.04–1.39)* | 1.25 (1.08–1.44)† | 1.22 (1.05–1.41)† | 1.22 (1.05–1.42)† | 1.41 (1.22–1.63)† | 1.17 (1.01–1.36)* |
| Anti-SSA single-positive SjD | 1.16 (0.94–1.44) | 1.00 (0.79–1.26) | 1.16 (0.93–1.45) | 1.14 (0.92–1.41) | 1.19 (0.96–1.48) | 1.14 (0.92–1.43) | 1.37 (1.12–1.68)† | 1.19 (0.97–1.47) |
| Anti-SSA/SSB double-positive SjD | 0.93 (0.76–1.14) | 0.91 (0.74–1.13) | 0.98 (0.80–1.20) | 0.95 (0.78–1.16) | 0.87 (0.71–1.07) | 0.94 (0.76–1.15) | 1.07 (0.88–1.31) | 0.93 (0.76–1.14) |
| Overlapping SjD with baseline HG | 1.31 (1.12–1.54)† | 1.24 (1.05–1.46)* | 1.32 (1.13–1.55)† | 1.30 (1.11–1.53)† | 1.29 (1.10–1.51)† | 1.32 (1.13–1.55)† | 1.52 (1.29–1.80)† | 1.28 (1.09–1.50)† |
| SLEDAI ≤ 4 | ||||||||
| Overlapping SjD | 1.16 (1.05–1.27)† | 1.09 (1.00–1.20) | 1.13 (1.04–1.24)† | 1.15 (1.05–1.26)† | 1.13 (1.04–1.24)† | 1.09 (0.99–1.19) | 1.21 (1.11–1.32)† | 1.13 (1.03–1.24)* |
| Anti-SSA single-positive SjD | 0.95 (0.83–1.08) | 0.90 (0.78–1.03) | 0.93 (0.81–1.07) | 0.94 (0.82–1.07) | 0.96 (0.84–1.09) | 0.96 (0.84–1.10) | 0.98 (0.86–1.12) | 0.95 (0.84–1.08) |
| Anti-SSA/SSB double-positive SjD | 1.05 (0.93–1.18) | 1.05 (0.93–1.19) | 1.07 (0.95–1.20) | 1.05 (0.93–1.19) | 1.03 (0.91–1.16) | 1.04 (0.92–1.18) | 1.10 (0.98–1.24) | 1.04 (0.92–1.18) |
| Overlapping SjD with baseline HG | 1.12 (1.01–1.23)* | 1.08 (0.98–1.19) | 1.12 (1.02–1.24)* | 1.12 (1.01–1.23)* | 1.12 (1.01–1.24)* | 1.12 (1.02–1.24)* | 1.20 (1.09–1.33)† | 1.10 (0.99–1.22) |
| No new SLE feature | ||||||||
| Overlapping SjD | 1.03 (0.94–1.13) | 0.99 (0.91–1.09) | 1.03 (0.95–1.13) | 1.03 (0.94–1.13) | 1.02 (0.93–1.12) | 1.00 (0.92–1.10) | 1.07 (0.98–1.17) | 1.02 (0.93–1.11) |
| Anti-SSA single-positive SjD | 0.94 (0.82–1.08) | 0.90 (0.79–1.04) | 0.94 (0.82–1.08) | 0.94 (0.82–1.07) | 0.95 (0.83–1.09) | 1.00 (0.88–1.15) | 0.99 (0.86–1.13) | 0.96 (0.84–1.09) |
| Anti-SSA/SSB double-positive SjD | 0.96 (0.85–1.08) | 0.96 (0.85–1.09) | 0.97 (0.86–1.09) | 0.96 (0.85–1.08) | 0.94 (0.84–1.07) | 0.96 (0.85–1.09) | 0.99 (0.88–1.11) | 0.96 (0.85–1.08) |
| Overlapping SjD with baseline HG | 1.06 (0.96–1.18) | 1.04 (0.94–1.15) | 1.08 (0.98–1.20) | 1.07 (0.96–1.18) | 1.08 (0.97–1.19) | 1.07 (0.97–1.19) | 1.14 (1.03–1.27)* | 1.07 (0.96–1.18) |
| No active organ involvement | ||||||||
| Overlapping SjD | 1.08 (0.98–1.18) | 1.05 (0.95–1.15) | 1.06 (0.97–1.16) | 1.08 (0.98–1.18) | 1.07 (0.97–1.17) | 1.00 (0.91–1.09) | 1.12 (1.02–1.22)* | 1.06 (0.96–1.16) |
| Anti-SSA single-positive SjD | 1.00 (0.88–1.14) | 0.95 (0.83–1.08) | 0.98 (0.86–1.12) | 0.99 (0.87–1.12) | 1.01 (0.89–1.14) | 0.99 (0.87–1.12) | 1.03 (0.91–1.17) | 1.00 (0.88–1.13) |
| Anti-SSA/SSB double-positive SjD | 0.99 (0.88–1.12) | 1.00 (0.88–1.13) | 1.00 (0.88–1.12) | 1.00 (0.88–1.13) | 0.97 (0.86–1.10) | 0.98 (0.87–1.11) | 1.02 (0.91–1.16) | 0.98 (0.87–1.11) |
| Overlapping SjD with baseline HG | 1.04 (0.94–1.16) | 1.02 (0.92–1.13) | 1.05 (0.95–1.16) | 1.04 (0.94–1.16) | 1.05 (0.95–1.17) | 1.01 (0.91–1.13) | 1.10 (0.99–1.22) | 1.03 (0.92–1.14) |
| Clinical RONT | ||||||||
| Overlapping SjD | 0.70 (0.54–0.91)† | 0.66 (0.51–0.85)† | 0.66 (0.51–0.86)† | 0.72 (0.56–0.93)* | 0.68 (0.53–0.88)† | 0.75 (0.58–0.97)* | 0.82 (0.63–1.06) | 0.66 (0.51–0.85)† |
| Anti-SSA single-positive SjD | 0.74 (0.52–1.05) | 0.81 (0.55–1.18) | 0.76 (0.54–1.07) | 0.75 (0.53–1.06) | 0.75 (0.53–1.07) | 0.74 (0.51–1.06) | 0.85 (0.60–1.21) | 0.79 (0.56–1.12) |
| Anti-SSA/SSB double-positive SjD | 0.49 (0.34–0.71)† | 0.51 (0.35–0.75)† | 0.58 (0.40–0.84)† | 0.50 (0.35–0.73)† | 0.43 (0.30–0.62)† | 0.49 (0.34–0.72)† | 0.58 (0.39–0.85)† | 0.49 (0.33–0.71)† |
| Overlapping SjD with baseline HG | 1.25 (0.98–1.58) | 1.16 (0.92–1.48) | 1.21 (0.95–1.55) | 1.25 (0.98–1.59) | 1.24 (0.98–1.57) | 1.32 (1.04–1.67)* | 1.36 (1.06–1.75)* | 1.21 (0.95–1.54) |
| Complete RONT | ||||||||
| Overlapping SjD | 0.61 (0.46–0.82)† | 0.58 (0.43–0.77)† | 0.55 (0.41–0.75)† | 0.63 (0.47–0.84)† | 0.59 (0.44–0.79)† | 0.68 (0.51–0.91)† | 0.70 (0.52–0.94)* | 0.57 (0.43–0.77)† |
| Anti-SSA single-positive SjD | 0.84 (0.58–1.22) | 0.79 (0.52–1.20) | 0.84 (0.58–1.22) | 0.85 (0.58–1.22) | 0.86 (0.59–1.24) | 0.91 (0.62–1.35) | 0.90 (0.62–1.31) | 0.88 (0.61–1.28) |
| Anti-SSA/SSB double-positive SjD | 0.46 (0.30–0.69)† | 0.46 (0.30–0.70)† | 0.48 (0.31–0.74)† | 0.47 (0.31–0.70)† | 0.39 (0.26–0.59)† | 0.44 (0.29–0.68)† | 0.50 (0.33–0.77)† | 0.46 (0.31–0.70)† |
| Overlapping SjD with baseline HG | 1.30 (1.01–1.68)* | 1.21 (0.94–1.56) | 1.25 (0.96–1.62) | 1.31 (1.01–1.69)* | 1.30 (1.01–1.68)* | 1.41 (1.09–1.81)† | 1.36 (1.04–1.78)* | 1.28 (0.99–1.65) |
| Normal serology | ||||||||
| Overlapping SjD | 0.84 (0.72–0.98)* | 0.83 (0.71–0.96)* | 0.81 (0.70–0.94)† | 0.86 (0.74–0.99)* | 0.83 (0.72–0.97)* | 0.92 (0.79–1.07) | 0.89 (0.77–1.04) | 0.84 (0.72–0.97)* |
| Anti-SSA single-positive SjD | 0.99 (0.82–1.20) | 0.93 (0.76–1.13) | 0.98 (0.81–1.18) | 1.00 (0.83–1.20) | 1.02 (0.85–1.23) | 1.08 (0.90–1.31) | 0.98 (0.81–1.19) | 0.99 (0.82–1.20) |
| Anti-SSA/SSB double-positive SjD | 0.63 (0.51–0.78)† | 0.64 (0.52–0.79)† | 0.64 (0.52–0.79)† | 0.64 (0.52–0.78)† | 0.60 (0.49–0.74)† | 0.64 (0.52–0.78)† | 0.67 (0.54–0.82)† | 0.63 (0.51–0.78)† |
| Overlapping SjD with baseline HG | 1.24 (1.07–1.43)† | 1.20 (1.03–1.38)* | 1.21 (1.05–1.40)† | 1.24 (1.07–1.43)† | 1.26 (1.09–1.45)† | 1.31 (1.14–1.52)† | 1.29 (1.11–1.50)† | 1.24 (1.07–1.44)† |
| Negative anti-dsDNA | ||||||||
| Overlapping SjD | 0.83 (0.73–0.95)† | 0.83 (0.73–0.94)† | 0.84 (0.74–0.95)† | 0.85 (0.75–0.96)* | 0.83 (0.73–0.95)† | 0.87 (0.77–0.99)* | 0.89 (0.78–1.01) | 0.83 (0.73–0.95)† |
| Anti-SSA single-positive SjD | 0.96 (0.81–1.12) | 0.96 (0.81–1.14) | 0.96 (0.82–1.13) | 0.96 (0.82–1.13) | 0.97 (0.83–1.14) | 1.00 (0.85–1.17) | 0.97 (0.82–1.14) | 0.95 (0.80–1.11) |
| Anti-SSA/SSB double-positive SjD | 0.65 (0.54–0.77)† | 0.67 (0.56–0.80)† | 0.69 (0.58–0.82)† | 0.65 (0.54–0.78)† | 0.62 (0.52–0.75)† | 0.66 (0.55–0.79)† | 0.68 (0.57–0.82)† | 0.65 (0.54–0.78)† |
| Overlapping SjD with baseline HG | 1.15 (1.01–1.31)* | 1.13 (0.99–1.29) | 1.15 (1.01–1.31)* | 1.16 (1.01–1.32)* | 1.17 (1.03–1.33)* | 1.21 (1.07–1.38)† | 1.20 (1.05–1.37)† | 1.16 (1.02–1.33)* |
| Normal complement | ||||||||
| Overlapping SjD | 1.13 (1.02–1.25)* | 1.05 (0.95–1.17) | 1.08 (0.98–1.20) | 1.13 (1.02–1.24)* | 1.11 (1.01–1.23)* | 1.14 (1.03–1.26)* | 1.16 (1.05–1.28)† | 1.11 (1.00–1.23)* |
| Anti-SSA single-positive SjD | 1.01 (0.87–1.17) | 0.87 (0.75–1.02) | 0.99 (0.86–1.15) | 1.02 (0.89–1.18) | 1.04 (0.90–1.20) | 1.10 (0.95–1.27) | 1.04 (0.90–1.20) | 1.03 (0.89–1.19) |
| Anti-SSA/SSB double-positive SjD | 1.04 (0.92–1.19) | 1.03 (0.90–1.18) | 1.03 (0.90–1.17) | 1.05 (0.92–1.20) | 1.02 (0.90–1.17) | 1.05 (0.92–1.20) | 1.07 (0.94–1.23) | 1.04 (0.91–1.18) |
| Overlapping SjD with baseline HG | 1.22 (1.09–1.36)† | 1.17 (1.05–1.31)† | 1.21 (1.08–1.34)† | 1.23 (1.10–1.37)† | 1.24 (1.11–1.38)† | 1.25 (1.12–1.39)† | 1.25 (1.12–1.40)† | 1.23 (1.10–1.37)† |
| PGA ≤ 1 | ||||||||
| Overlapping SjD | 1.06 (0.98–1.16) | 1.02 (0.94–1.11) | 1.05 (0.96–1.14) | 1.06 (0.97–1.15) | 1.05 (0.96–1.14) | 1.03 (0.94–1.12) | 1.10 (1.01–1.20)* | 1.03 (0.94–1.12) |
| Anti-SSA single-positive SjD | 0.95 (0.84–1.08) | 0.90 (0.79–1.02) | 0.94 (0.83–1.07) | 0.94 (0.83–1.07) | 0.96 (0.85–1.09) | 1.00 (0.88–1.13) | 0.98 (0.87–1.11) | 0.96 (0.85–1.08) |
| Anti-SSA/SSB double-positive SjD | 0.98 (0.87–1.10) | 0.98 (0.87–1.10) | 0.97 (0.87–1.09) | 0.98 (0.87–1.10) | 0.96 (0.86–1.08) | 0.98 (0.88–1.10) | 1.01 (0.90–1.13) | 0.97 (0.87–1.09) |
| Overlapping SjD with baseline HG | 1.05 (0.96–1.16) | 1.03 (0.94–1.14) | 1.07 (0.97–1.17) | 1.06 (0.96–1.17) | 1.07 (0.97–1.18) | 1.06 (0.96–1.17) | 1.13 (1.02–1.24)* | 1.04 (0.94–1.15) |
| Pred ≤ 5 mg/d | ||||||||
| Overlapping SjD | 1.20 (1.04–1.38)* | 1.05 (0.91–1.21) | 1.16 (1.00–1.33)* | 1.20 (1.04–1.38)* | 1.17 (1.01–1.34)* | 1.18 (1.03–1.36)* | 1.31 (1.14–1.51)† | 1.12 (0.98–1.29) |
| Anti-SSA single-positive SjD | 1.15 (0.93–1.42) | 1.03 (0.83–1.28) | 1.16 (0.94–1.44) | 1.12 (0.91–1.39) | 1.19 (0.97–1.47) | 1.14 (0.92–1.42) | 1.33 (1.09–1.63)† | 1.20 (0.98–1.47) |
| Anti-SSA/SSB double-positive SjD | 0.81 (0.67–0.99)* | 0.78 (0.64–0.97)* | 0.84 (0.69–1.02) | 0.83 (0.68–1.01) | 0.76 (0.63–0.93)† | 0.83 (0.68–1.01) | 0.89 (0.74–1.09) | 0.81 (0.67–0.98)* |
| Overlapping SjD with baseline HG | 1.16 (1.00–1.36) | 1.10 (0.94–1.29) | 1.18 (1.01–1.37)* | 1.16 (1.00–1.35) | 1.15 (0.99–1.33) | 1.20 (1.03–1.39)* | 1.30 (1.11–1.52)† | 1.13 (0.97–1.32) |
| No immunosuppressant | ||||||||
| Overlapping SjD | 1.02 (0.88–1.17) | 0.93 (0.80–1.08) | 0.98 (0.84–1.13) | 1.05 (0.91–1.21) | 1.01 (0.88–1.17) | 0.94 (0.81–1.09) | 1.10 (0.95–1.27) | 0.99 (0.86–1.15) |
| Anti-SSA single-positive SjD | 1.05 (0.88–1.25) | 0.94 (0.78–1.13) | 1.04 (0.87–1.24) | 1.03 (0.87–1.23) | 1.08 (0.91–1.29) | 0.89 (0.74–1.08) | 1.11 (0.92–1.33) | 1.09 (0.91–1.29) |
| Anti-SSA/SSB double-positive SjD | 0.63 (0.51–0.78)† | 0.59 (0.47–0.74)† | 0.64 (0.52–0.79)† | 0.64 (0.52–0.79)† | 0.61 (0.50–0.76)† | 0.61 (0.50–0.76)† | 0.69 (0.56–0.85)† | 0.63 (0.51–0.77)† |
| Overlapping SjD with baseline HG | 1.07 (0.93–1.24) | 0.99 (0.86–1.15) | 1.08 (0.93–1.24) | 1.08 (0.93–1.24) | 1.08 (0.93–1.25) | 1.03 (0.89–1.19) | 1.23 (1.05–1.42)† | 1.04 (0.90–1.20) |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSystemic Lupus Erythematosus Research · Salivary Gland Disorders and Functions · Atherosclerosis and Cardiovascular Diseases
Background
Accumulating evidence has confirmed that treat-to-target strategies greatly reduce organ damage accumulation and subsequent flares in patients with systemic lupus erythematosus (SLE). Treatment aiming to reach remission or lupus low disease activity state (LLDAS), in SLE patients, has been recommended (1). Because of the inherent heterogeneity in patient characteristics and disease manifestations, as well as various influencing factors, the proportion of SLE patients who can achieve remission or LLDAS varies greatly among reports. Thus, clarifying the effects of these factors on treatment outcomes is expected to optimize therapeutic regimens (2, 3).
Sjögren’s disease (SjD) has long been recognized as the most common connective tissue disease co-occurring with SLE, occurring in approximately 6.5% to 14.5% of SLE patients (4–6). Cross-sectional studies have shown that patients with SLE overlapping SjD, who are considered a unique subgroup, exhibit distinct clinical and immunological features (4, 6, 7). Overlapping SjD is usually associated with specific immunological characteristics in SLE patients, such as a high prevalence of anti-SSA and anti-SSB antibodies and hypergammaglobulinemia. However, whether overlapping SjD per se and its different subgroups act as protective or detrimental factors for SLE patients in achieving remission or LLDAS remains unclear. Many factors influencing outcomes, including gender, age, SLE duration, baseline disease activity status, therapeutic intensity, and organ involvement, may also inevitably act as confounding factors (8–10).
Therefore, we aimed to explore the impact of overlapping SjD and its immunological characteristics on treatment target achievement in patients with SLE. We used propensity score matching (PSM) to adjust for known confounding factors.
Methods
Study subjects
The current study was conducted based on the Peking University First Hospital SLE (PKUFHS) cohort, which has been established since 2007. Patients who fulfilled the 1997 American College of Rheumatology (ACR), or 2012 Systemic Lupus International Collaborating Clinics (SLICC), classification criteria for SLE, were aged ≥18 years, and had at least three clinic visits were enrolled (11, 12). SjD was diagnosed using the 2016 ACR/European Alliance of Associations for Rheumatology (EULAR) classification criteria (13). Their medical records through June 2019 were reviewed.
Gender, age of onset, disease duration, baseline therapeutic regimen details, SLE Disease Activity Index (SLEDAI), Physician Global Assessment (PGA), organ involvement (e.g., renal, hematological, neuropsychiatric, and hepatic), serum immunoglobulin G (IgG) level, and the status of clinical or complete remission on treatment (RONT) or LLDAS at each visit were extracted (14, 15). LLDAS, RONT, and relevant components were set as outcomes. The study was approved by the institutional research ethics committee, and all patients provided informed consent for their medical records to be collected.
Definitions of SjD immunological characteristics
Both anti-SSA and anti-SSB antibodies were detected using an immunoblotting assay. Hypergammaglobulinemia was defined as serum IgG > 16.85 g/L, measured by rate nephelometry. In patients with SLE overlapping SjD, the immunological features of SjD were categorized into three subgroups, namely, anti-SSA single-positive SjD, anti-SSA/SSB double-positive SjD, and SjD with baseline hypergammaglobulinemia. SLE patients without SjD were called the No-SjD group.
RONT and LLDAS definitions
Definition of Remission In SLE (DORIS) was used to define remission, including clinical SLEDAI = 0 with PGA < 0.5, of which RONT allowed prednisone 5 mg/d at most and maintenance immunosuppressants. Complete RONT further requires normal serology (anti-dsDNA and complements) (8). LLDAS was defined as SLEDAI ≤ 4, with no activity score in cardiopulmonary, renal, central nervous system, vasculitis, or gastrointestinal involvement or hemolytic anemia; no new features compared with the last visit; PGA ≤ 1; prednisone dose ≤ 7.5 mg/d; and well-tolerated maintenance doses of immunosuppressants (14). The status of clinical/complete RONT, LLDAS, and their components was evaluated at each visit. To describe the overall condition, the following were calculated: the proportion of patients reaching the target range at least once, the accumulated time spent within the target range, and the time to first achievement of the target. These metrics were stratified by SjD immunological characteristics of interest.
The PSM method
To control for confounders affecting RONT or LLDAS achievement in SLE patients, both known and potential variables, including gender, age of onset, SLE duration, baseline disease activity, baseline therapeutic intensity, renal involvement, hematological involvement, neuropsychiatric involvement, and hepatic involvement, were included in the logistic regression model to estimate propensity scores. Standardized mean differences were used to confirm that the groups were adequately matched. Specifically, baseline therapeutic intensity was adopted and demonstrated to be effective in the Hopkins cohort in simplifying heterogeneous therapeutic regimens. Low therapeutic intensity was defined as daily prednisone ≤ 5 mg or equivalent without immunosuppressants, while baseline disease activity was defined according to LLDAS (8). For each SLE patient with a specific immunological feature, propensity score-matched patients in the No-SjD group were selected using a 1:3 nearest neighbor matching algorithm.
Statistical analysis
A Cox proportional hazards model with recurrent event data was used to analyze the effects of SjD and its immunological characteristics on the attainment of clinical and complete RONT, as well as LLDAS, which could be achieved multiple times during follow-up. Time-varying treatment variables after baseline were also included in the Cox model. The analysis was performed in both unmatched and matched cohorts to estimate the unadjusted and adjusted effects of SjD and its immunological characteristics, respectively. Additionally, subgroup analyses stratified by the aforementioned confounders were conducted.
All outcomes were presented as hazard ratios (HRs) with 95% confidence intervals (CIs). Values were presented as n (%) for categorical variables and median [interquartile range (IQR)] for numerical variables. Two-sided p-values were used, with values of 0.05 or less considered statistically significant. All statistical analyses were conducted using Stata (version 14.0).
Results
General features of SLE with/without SjD and its immunological characteristics
A total of 626 SLE patients with 9,415 visits were enrolled in the study. The median follow-up period was 52 months. Among the 626 patients, 77 (12.3%) were recognized as having SLE with overlapping SjD, 35 (5.6%) as having anti-SSA single-positive SjD, 34 (5.4%) as having anti-SSA/anti-SSB double-positive SjD, and 51 (8.1%) as having SjD with baseline hypergammaglobulinemia. Among the 69 total anti-SSA-positive SjD patients, 35 (50.7%) showed single anti-SSA positivity, and the rest showed double positivity for anti-SSA and anti-SSB. Except for the SLE patients with double-positive SjD, the median age at onset of those with overlapping SjD and all other immunological subgroups was at least 10 years older, with a significantly higher female predominance than the No-SjD group. In addition, a significantly higher proportion of hematological involvement was observed in SLE patients with overlapping SjD and those with anti-SSA single-positive SjD (Supplementary Table S1).
Impact of SjD and its immunological characteristics on RONT/LLDAS
In general, the occurrence of LLDAS, clinical RONT, and complete RONT at least once in SLE patients with baseline hypergammaglobulinemia was significantly more frequent than in the No-SjD group (80.4% vs. 64.7%, 56.9% vs. 39.7%, and 52.9% vs. 34.8%, respectively). The proportion of time maintained in LLDAS and in clinical and complete RONT among SjD patients with baseline hypergammaglobulinemia, as well as in complete RONT among anti-SSA single-positive SjD patients, showed a similar tendency. Regarding SLE patients with overlapping SjD (including those with anti-SSA single-positive and anti-SSA/SSB double-positive SjD), the time to first RONT was slightly longer than that in the No-SjD group (Table 1).
The groups of interest were well balanced with the No-SjD group after PSM based on the aforementioned known confounders (Supplementary Table S1). Independent of known confounders, overlapping SjD was associated with a 24% higher probability of reaching LLDAS, a 29% lower probability of reaching clinical RONT, and a 38% lower probability of reaching complete RONT. Anti-SSA/SSB double-positive SjD reduced the probability of reaching RONT and achieving normal serology to approximately 50% and 65%, respectively, compared with those of the No-SjD group. In contrast, SjD with hypergammaglobulinemia was associated with a 12% to 31% higher probability of achieving LLDAS, complete RONT, and its component achievements; anti-SSA single-positive SjD showed no significant impact (Table 2).
Regarding the components, normal serology was affected in patients with overlapping SjD, double-positive SjD, and SjD with baseline hypergammaglobulinemia. Both achieving a PGA ≤ 1 and the absence of immunosuppressant treatment were 12% to 23% more attainable in SLE patients with overlapping SjD and SjD with baseline hypergammaglobulinemia.
Sensitivity analyses
The impact of specific immunological characteristics of SjD on the achievement of clinical or complete RONT and LLDAS was mostly consistent across subgroups of SLE patients stratified by critical confounders. Similarly, the target components in SLE patients showed consistent results in these subgroups (Table 3).
Discussion
Our study examined the influence of SjD immunological characteristics on the achievement of remission and LLDAS, as well as on related clinical components in SLE patients. This analysis was conducted using the PSM method in a real-world cohort with a median follow-up of 4.3 years.
Overall, anti-SSA-positive SjD patients were either positive for anti-SSA alone or positive for both anti-SSA and anti-SSB. This confirms that isolated positivity for anti-SSB alone is rare in SjD patients (16). The comparison of general characteristics related to critical influencing factors before matching indicated that SLE patients with different SjD immunological characteristics tended to be older at the onset of SLE, showed a significant predominance of female patients, and had more frequent hematological involvement. These findings are largely consistent with those of De Marchi G et al. and Jiménez PP et al. (17, 18). All these characteristics may collectively contribute to a variable probability of reaching remission, making the exploration of their net effect important but challenging.
Overlapping SjD and its immunological characteristics showed differing effects on the achievement of clinical and complete RONT and LLDAS in SLE patients. The hindrance to achieving further remission beyond LLDAS and the inconsistent results observed in composite clinical outcomes and their relevant components in cases of overlapping SjD suggest that opposing mechanisms may be involved. These results suggest that SLE patients with SjD who have reached LLDAS should continue to be closely monitored. Intensive treatment should be given to achieve clinical remission to reduce the risk of irreversible organ damage and steroid-related adverse events. Correspondingly, both the adverse impact of SjD patients double-positive for anti-SSA and anti-SSB antibodies and the protective effect of SjD patients presenting with baseline hypergammaglobulinemia were confirmed.
Analyzing the impact on the components of RONT and LLDAS could further facilitate understanding the correlation between SjD characteristics and SLE. On the one hand, SjD with baseline hypergammaglobulinemia facilitated achieving targets for all the components of RONT, indicating a more controllable course. On the other hand, despite the insignificant influence of single anti-SSA positivity, double positivity for anti-SSA and anti-SSB antibodies impeded achieving normal serological markers. The possible explanations for these contrasting impacts are as follows.
First, the genetic link between the diseases is significant. Increasing research on the genetic connections has provided a clearer understanding of SLE and SjD. Tumor necrosis factor alpha inducible protein 3 (TNFAIP3) encodes the deubiquitinase A20 and acts as a negative regulator of the inflammatory cascade. Moreover, the rs6920220 single-nucleotide polymorphism of TNFAIP3 has been shown to be associated with susceptibility to both SLE and SjD (19). Recently, Kamitaki et al. reported that the decreased copy number of the C4 gene was associated with a sevenfold higher risk for SLE and a 16-fold higher risk for SjD (20).
Second, there is crosstalk among autoantibodies. On the one hand, SSA has been shown to directly participate in systemic inflammation by promoting immune complex formation and subsequent cytokine production. Ro60 was considered a quality checkpoint of RNAs by tagging misfolded RNAs for further degradation and epitope spreading. Meanwhile, Ro52, as an E3 ubiquitin ligase, negatively regulates the interferon-mediated immune response (21, 22). On the other hand, the nucleic acid components associated with SSB were transcripts synthesized by RNA polymerase III. These transcripts may interact with small RNAs, such as those encoded by Epstein–Barr virus or hepatitis C virus, which can induce autoantibody production (23–25). Under certain circumstances, such as apoptosis, SSA and SSB antigens can be translocated to the cell surface, where they are bound by anti-SSA/SSB antibodies. This binding initiates antibody-dependent cell-mediated cytotoxicity and induces the production of new autoantibodies (26). Furthermore, Ro60 and SSB transiently cooperate, facilitating antigen spreading to other associated autoantigens once the immune response is evoked (27, 28). Such mechanisms laid the foundation for the multiplicative effect of anti-SSB antibody positivity on anti-SSA positivity alone, as observed in our cohorts.
Third, the presence of baseline hypergammaglobulinemia—an elevated level of immunoglobulins in the blood—often indicates more active immune abnormalities in patients with SjD. This activity may increase the likelihood of reversing active lesions. Clinically, doctors prefer to choose more aggressive therapeutic agents for patients with elevated globulin levels, including traditional immunosuppressive drugs and biological agents that are more effective in inducing B-cell depletion and presumably help SLE patients achieve LLDAS more effectively. However, more research is needed to clarify the biological significance of hypergammaglobulinemia in SLE patients, particularly in those with SjD.
The impact of overlapping SjD in SLE patients is not as mild as reported in cross-sectional studies, and it is postulated that these patients are more likely to reach RONT (18). Accordingly, there was discordance between the actual harm caused by SjD immunological features and the PGA. The hazardous net effect verified by the current study can be attributed to the mutual reinforcement of the underlying mechanisms and adequate adjustment for relevant confounding factors. Based on the discussion above, the coexistence of SjD and baseline hypergammaglobulinemia generally facilitates achieving treatment targets, while anti-SSA/SSB double-positive SjD significantly delays SLE patients from achieving treatment targets across nearly all composite outcomes and their relevant components. It would be appropriate for these patients to monitor their disease activity more closely and to intensify treatment to help them achieve clinical remission.
The limitations of the study mainly include the following. There was a relatively low frequency of overlapping SjD in our SLE cohort. The study was retrospective and conducted in a single-center cohort. There was potential for referral bias at a tertiary center and its impact on the observed frequency of overlap SjD. However, the data were complete and representative, and several articles based on this cohort have been published (29, 30).
Conclusions
Overlapping SjD independently prevented SLE patients from achieving further RONT from LLDAS. Among these factors, anti-SSA/SSB double positivity exhibited a hazardous effect, whereas baseline hypergammaglobulinemia acted as a protective factor.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Fanouriakis A Kostopoulou M Alunno A Aringer M Bajema I Boletis JN. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. (2019) 78:736–45. doi: 10.1136/annrheumdis-2019-215089, PMID: 30926722 · doi ↗ · pubmed ↗
- 2Gao D Hao Y Mu L Xie W Fan Y Ji L. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus. Rheumatol (Oxford). (2020) 59:3400–7. doi: 10.1093/rheumatology/keaa 120, PMID: 32337549 · doi ↗ · pubmed ↗
- 3Golder V Kandane-Rathnayake R Bun Hoi AY Huq M Louthrenoo W An Y. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther. (2016) 18:260. doi: 10.1186/s 13075-016-1163-2, PMID: 27829463 PMC 5103412 · doi ↗ · pubmed ↗
- 4Baer AN Maynard JW Shaikh F Magder LS Petri M. Secondary Sjogren's syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol. (2010) 37:1143–9. doi: 10.3899/jrheum.090804, PMID: 20360189 · doi ↗ · pubmed ↗
- 5Pan HF Ye DQ Wang Q Li WX Zhang N Li XP. Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients. Clin Rheumatol. (2008) 27:339–43. doi: 10.1007/s 10067-007-0720-0, PMID: 17899309 · doi ↗ · pubmed ↗
- 6Manoussakis MN Georgopoulou C Zintzaras E Spyropoulou M Stavropoulou A Skopouli FN. Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome. Arthritis Rheum. (2004) 50:882–91. doi: 10.1002/art.20093, PMID: 15022331 · doi ↗ · pubmed ↗
- 7Ruacho G Kvarnström M Zickert A Oke VRönnelid J Eketjäll S. Sjögren syndrome in systemic lupus erythematosus: A subset characterized by a systemic inflammatory state. J Rheumatol. (2020) 47:865–75. doi: 10.3899/jrheum.190250, PMID: 31523050 · doi ↗ · pubmed ↗
- 8Wilhelm TR Magder LS Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. (2017) 76:547–53. doi: 10.1136/annrheumdis-2016-209489, PMID: 27558987 · doi ↗ · pubmed ↗